Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Omalizumab, licensed for patients with uncontrolled persistent allergic (IgE mediated) asthma, was found to be cost-effective based upon its clinical trial data. Observational studies have been undertaken to determine the real life outcomes of using omalizumab in the community. OBJECTIVE: To determine the cost-effectiveness of omalizumab based upon observational data from the Netherlands and compare to its cost-effectiveness using clinical trial data. METHODS: An observational study (eXpeRience) recruited allergic asthma patients eligible for Omalizumab therapy and followed them while on treatment. At 1 year, data from the Dutch patients enrolled in eXpeRience were examined to estimate the number of exacerbations and resource use while on omalizumab therapy compared to the year prior to omalizumab use. Observational data were used in a Markov model to calculate the lifetime cost-effectiveness ratios. RESULTS: In the 1 year prior to omalizumab therapy the per-person rate of exacerbations was 3.39 compared to 1.07 in the year taking omalizumab. The discounted incremental lifetime additional costs for omalizumab were €55,865 for 1.46 additional quality-adjusted life years (QALY), resulting in €38,371/QALY. Using the INNOVATE clinical trial outcomes and current resource use, the prior ratio was €34,911/QALY, similar to the observational ratio. As in all observational studies, the main limitation is obtaining complete and accurate data. Patients with missing exacerbation or response data were excluded from this analysis. CONCLUSION: Non-clinical trial experience with omalizumab supported the finding of fewer exacerbations in the allergic asthma population while treated with omalizumab, and therapy was found to continue to have an attractive cost-effectiveness ratio.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vignola, A. M., Humbert, M., Bousquet, J., Boulet, L., Hedgecock, S., Blogg, M., Fox, H., & Surrey, K. (2004) · Allergy · doi:10.1111/j.1398-9995.2004.00550.x · Cited by 405
Cited by
Saturni, S., Bellini, F., Braido, F., Paggiaro, P., Sanduzzi, A., Scichilone, N., Santus, P. A., Morandi, L., & Papi, A. (2014) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2014.01.005 · Cited by 245
Lai, T., Wang, S., Xu, Z., Zhang, C., Zhao, Y., Hu, Y., Cao, C., Ying, S., Chen, Z., Li, W., et al. (2015) · Scientific Reports · doi:10.1038/srep08191 · Cited by 103
Larsson, K., Ställberg, B., Lisspers, K., Telg, G., Johansson, G., Thuresson, M., & Janson, C. (2018) · Respiratory Research · doi:10.1186/s12931-018-0719-x · Cited by 100
“Swedish recommendations on asthma management are similar to the GINA guidelines [2], in which it is recommended that severe asthma should be managed by respiratory/allergy specialists [2, 5, 9].”
Method
Metadata
- Authors
- van Nooten, F., Stern, S., Braunstahl, G.-J., Thompson, C., Groot, M., & Brown, R. E.
- Venue
- Journal of Medical Economics
- Publisher
- Informa Healthcare
- Published
- 2012-12-18
- Volume
- 16
- Issue
- 3
- Pages
- 342-348
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W2157768075
- Cited by
- 52
- References
- 1
- FWCI
- 3.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. https://app.cochat.ai/papers/10.3111/13696998.2012.756398
- The paper
- van Nooten, F., Stern, S., Braunstahl, G.-J., Thompson, C., Groot, M., & Brown, R. E. (2013). Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. Journal of Medical Economics. https://doi.org/10.3111/13696998.2012.756398
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.